Evidence map›Paper›PMID 25512481›Full record

ArticleThe Journal of rheumatology2015

Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort.

Abha G Singh, Tanaz A Kermani, Cynthia S Crowson, Cornelia M Weyand, Eric L Matteson, Kenneth J Warrington

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Predictors of Permanent Vision Loss in Giant Cell Arteritis.Neuro-ophthalmology (Aeolus Press) · 2025
    Article
  11. Retinal Artery Occlusion: A Review of Current Management Practices.Journal of ophthalmic & vision research · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Abha G SinghFrom the Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, University of California, Los Angeles; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.A.G. Singh, MBBS, Division of Rheumatology, Mayo Clinic; T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; C.S. Crowson, MS, Division of Rheumatology, Mayo Clinic; C.M. Weyand, MD, PhD, Division of Immunology and Rheumatology, Stanford University School of Medicine; E.L. Matteson, MD, MPH; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic.
Tanaz A KermaniFrom the Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, University of California, Los Angeles; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.A.G. Singh, MBBS, Division of Rheumatology, Mayo Clinic; T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; C.S. Crowson, MS, Division of Rheumatology, Mayo Clinic; C.M. Weyand, MD, PhD, Division of Immunology and Rheumatology, Stanford University School of Medicine; E.L. Matteson, MD, MPH; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic.
Cynthia S CrowsonFrom the Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, University of California, Los Angeles; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.A.G. Singh, MBBS, Division of Rheumatology, Mayo Clinic; T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; C.S. Crowson, MS, Division of Rheumatology, Mayo Clinic; C.M. Weyand, MD, PhD, Division of Immunology and Rheumatology, Stanford University School of Medicine; E.L. Matteson, MD, MPH; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic.
Cornelia M WeyandFrom the Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, University of California, Los Angeles; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.A.G. Singh, MBBS, Division of Rheumatology, Mayo Clinic; T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; C.S. Crowson, MS, Division of Rheumatology, Mayo Clinic; C.M. Weyand, MD, PhD, Division of Immunology and Rheumatology, Stanford University School of Medicine; E.L. Matteson, MD, MPH; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic.
Eric L MattesonFrom the Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, University of California, Los Angeles; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.A.G. Singh, MBBS, Division of Rheumatology, Mayo Clinic; T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; C.S. Crowson, MS, Division of Rheumatology, Mayo Clinic; C.M. Weyand, MD, PhD, Division of Immunology and Rheumatology, Stanford University School of Medicine; E.L. Matteson, MD, MPH; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic.
Kenneth J WarringtonFrom the Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, University of California, Los Angeles; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.A.G. Singh, MBBS, Division of Rheumatology, Mayo Clinic; T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; C.S. Crowson, MS, Division of Rheumatology, Mayo Clinic; C.M. Weyand, MD, PhD, Division of Immunology and Rheumatology, Stanford University School of Medicine; E.L. Matteson, MD, MPH; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic. warrington.kenneth@mayo.edu.
Mayo Clinic · USMayo Clinic in Florida · USStanford University · USUniversity of California, Los Angeles · USUniversity of Southern California · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
The NOTCH Signaling Pathway in Large Vessel VasculitisR01HL117913 · NHLBI · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 2014 to 2025
$5.0M
NCATS NIH HHS UL1 TR000135NHLBI NIH HHS R01 HL117913NIA NIH HHS R01 AG034676NIA NIH HHS R01AG034676
6 · The paper itself

Abstract

objectiveTo evaluate clinical characteristics, treatment, and outcomes of patients with visual changes from giant cell arteritis (GCA) and to examine trends over the last 5 decades.

methodsWe reviewed the medical records of a population-based cohort of patients with GCA diagnosed between 1950 and 2004. The clinical, ophthalmological, and laboratory features of patients with visual manifestations attributable to GCA were compared to patients without visual complications. Trends over time were examined using logistic regression modeling adjusted for age and sex.

resultsIn a cohort of 204 cases of GCA (mean age 76.0 ± 8.2 yrs, 80% female), visual changes from GCA were observed in 47 patients (23%), and 4.4% suffered complete vision loss. A higher proportion of patients with visual manifestations reported jaw claudication than did patients without visual changes (55% vs 38%, p = 0.04). Over a period of 55 years, we observed a significant decline in the incidence of visual symptoms due to GCA. There was a lower incidence of ischemic optic neuropathy in the 1980-2004 cohort vs 1950-1979 (6% vs 15%, p = 0.03). Patients diagnosed in later decades were more likely to recover from visual symptoms (HR 1.34, 95% CI 1.06-1.71). Chances of recovery were poor in patients with anterior ischemic optic neuropathy or complete vision loss.

conclusionIncidence of visual symptoms has declined over the past 5 decades, and chances of recovery from visual symptoms have improved. However, complete loss of vision is essentially irreversible. Jaw claudication is associated with higher likelihood of development of visual symptoms.

Indexed as

Adrenal Cortex HormonesAgedAged, 80 and overFemaleGiant Cell ArteritisHumansMaleRetrospective StudiesVision DisordersAdrenal Cortex HormonesBLINDNESSGIANT CELL ARTERITISSTEROIDSVASCULITISVISION LOSSVISUAL MANIFESTATIONS

Identifiers

PMID25512481
PMCPMC4367485
OpenAlexW2046402806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.